PROSPECTIVEEVALUATION OF SYMPTOMS AND OPEN LABEL HALOPERIDOL IN CANNABINOID HYPEREMESIS SYNDROME (HALO).

Registry ID

CHS-HA-001

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

UNIVERSITY OF CALGARY

Start date

2020-03-01

Last update

2020-02-19

Conditions

• NAUSEA

Related clinical trials

• FORESIGHT: FEASIBILITY OF OLANZAPINE AT REDUCED DOSE IN HIGHLY EMETOGENIC CHEMOTHERAPY: A RANDOMISED CONTROLLED TRIAL AGAINST APREPITANT IN TRIPLE THERAPY

View on source registry